phe885
novartis
['phe885', 'mmsm', 'multiple myeloma']
increased objective response rates, high minimal residual negativity rates, and no new safety signals were observed when phe885 was utilized in patients with relapsed/refractory multiple myeloma. #mmsm #asco23 | 
Home of the journal ONCOLOGY®, CancerNetwork® offers different perspectives on oncology/hematology through review articles, news, podcasts, blogs, and more.